8156 — Sinopharm Tech Holdings Income Statement
0.000.00%
Last trade - 00:00
- HK$18.37m
- HK$13.68m
- HK$42.84m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 43.5 | 166 | 77.8 | 41 | 42.8 |
Cost of Revenue | |||||
Gross Profit | 23.7 | 44.7 | 20.9 | 5.93 | 5.47 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 79.5 | 314 | 178 | 119 | 45.9 |
Operating Profit | -36 | -148 | -100 | -77.6 | -3.02 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -47.9 | -165 | -111 | -94.2 | -11.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -45.6 | -164 | -111 | -93.8 | -10.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -46.8 | -161 | -106 | -88 | -10.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -46.8 | -161 | -106 | -88 | -10.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.019 | -0.462 | -0.458 | -0.442 | 0.014 |